{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:10:58Z","timestamp":1717492258426},"reference-count":13,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2014]]},"DOI":"10.1536\/ihj.14-217","type":"journal-article","created":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T23:55:54Z","timestamp":1413417354000},"page":"482-483","source":"Crossref","is-referenced-by-count":11,"title":["Aquaporin-2-Guided Tolvaptan Therapy in Patients With Congestive Heart Failure Accompanied by Chronic Kidney Disease"],"prefix":"10.1536","volume":"55","author":[{"given":"Teruhiko","family":"Imamura","sequence":"first","affiliation":[{"name":"Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. Circ J 2014; 78: 844-52.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kinugawa K, Imamura T, Komuro I. Experience of a vasopressin receptor antagonist, tolvaptan, under the unique indication in Japanese heart failure patients. Clin Pharmacol Ther 2013; 94: 449-51.","DOI":"10.1038\/clpt.2013.147"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Imamura T, Kinugawa K, Shiga T, <i>et al<\/i>. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.","DOI":"10.1253\/circj.CJ-12-0971"},{"key":"4","unstructured":"4. Sato E, Nakamura T, Amaha M, <i>et al<\/i>. Effect of tolvaptan on patients with chronic kidney disease due to diabetic nephropathy with heart failure. Int Heart J (in press)"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Fushimi K, Uchida S, Hara Y, Hirata Y, Marumo F, Sasaki S. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature 1993; 361: 549-52.","DOI":"10.1038\/361549a0"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sasaki S, Fushimi K, Saito H, <i>et al<\/i>. Cloning, characterization, and chromosomal mapping of human aquaporin of collecting duct. J Clin Invest 1994; 93: 1250-6.","DOI":"10.1172\/JCI117079"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Radin MJ, Yu MJ, Stoedkilde L, <i>et al<\/i>. Aquaporin-2 regulation in health and disease. Vet Clin Pathol 2012; 41: 455-70. (Review)","DOI":"10.1111\/j.1939-165x.2012.00488.x"},{"key":"8","unstructured":"8. Imamura T, Kinugawa K, Fujino T, <i>et al<\/i>. Increased Urine Aquaporin-2 Relative to Plasma Arginine Vasopressin Is a Novel Marker of Response to Tolvaptan in Patients With Decompensated Heart Failure. Circ J (in press)"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rai T, Sekine K, Kanno K, <i>et al<\/i>. Urinary excretion of aquaporin-2 water channel protein in human and rat. J Am Soc Nephrol 1997; 8: 1357-62.","DOI":"10.1681\/ASN.V891357"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Konstam MA, Gheorghiade M, Burnett JC Jr, <i>et al<\/i>. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.","DOI":"10.1001\/jama.297.12.1319"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Imamura T, Kinugawa K, Minatsuki S, <i>et al<\/i>. Urine sodium excretion after tolvaptan administration is dependent upon baseline serum sodium levels: a possible explanation for the improvement of hyponatremia with scarce chance of hypernatremia by a vasopressin receptor antagonist. Int Heart J 2014; 55: 131-7.","DOI":"10.1536\/ihj.13-221"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Imamura T, Kinugawa K, Minatsuki S, <i>et al<\/i>. Tolvaptan can improve clinical course in responders. Int Heart J 2013; 54: 377-81.","DOI":"10.1536\/ihj.54.377"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Imamura T, Kinugawa K, Ohtani T, <i>et al<\/i>. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: design and rationale of the AQUA-TLV study. Int Heart J 2014; 55: 264-7.","DOI":"10.1536\/ihj.13-326"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/6\/55_14-217\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:55:57Z","timestamp":1650416157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/55\/6\/55_14-217\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.14-217","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}